vitalwiki

Desonide

RxNorm 204135· DESONIDE· TOPICAL

Corticosteroid [EPC] · Alembic Pharmaceuticals Inc.

Indications and usage

INDICATIONS AND USAGE Desonide ointment USP, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

Dosage and administration

DOSAGE AND ADMINISTRATION Desonide ointment USP, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide ointment USP, 0.05% should not be used with occlusive dressings.

Contraindications

CONTRAINDICATIONS Desonide ointment USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse events

Most frequently reported events (FDA FAERS). Report frequency does not imply causation.

  • drug ineffective1,161
  • macular degeneration780
  • off label use409
  • pain384
  • nausea371
  • headache320
  • rash313
  • pruritus310
  • erythema308
  • pyrexia301
  • psoriasis280
  • malaise279
  • weight decreased277
  • therapeutic product effect incomplete263
  • abdominal pain223
  • dermatitis atopic221

Adverse reactions (label)

ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide ointment USP, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation. To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .